ADC Therapeutics (ADCT) Inventory Average (2021 - 2026)

ADC Therapeutics (ADCT) has reported Inventory Average for 6 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.

• Quarterly Inventory Average fell 54.51% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 54.51% YoY) and the FY2025 annual result came in at $3.2 million, down 65.08% from the prior year.
• Inventory Average retreated to $4.5 million in Q1 2026 per ADCT's latest filing, from $11.1 million in the prior quarter.
• Over the last five years, Inventory Average for ADCT reached as high as $21.1 million in Q3 2023 and fell as low as $4.5 million in Q1 2026.
• A 5-year average of $14.5 million and a median of $15.2 million in 2022 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2022 — Inventory Average surged 93.28% — and 2026, when it tumbled 54.51%.
• Year by year, Inventory Average stood at $13.9 million in 2022, then jumped by 39.86% to $19.5 million in 2023, then tumbled by 52.9% to $9.2 million in 2024, then rose by 21.3% to $11.1 million in 2025, then sank by 59.69% to $4.5 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $4.5 million, $11.1 million, and $17.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.